A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.
CONCLUSIONS: The clinical activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.
PMID: 26655846 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Goff LW, Cohen RB, Berlin J, De Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Gallo Stampino C, Abbattista A, Wang E, Borghaei H Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Perfusion | Renal Cell Carcinoma | Study | Thrombocytopenia | Toxicology | Ultrasound